GNOS Genosis

RNS Number:8715U
Genosis PLC
16 April 2007


For Immediate Release                                     16 April 2007


                                  Genosis PLC


      Signs up major US retailer CVS to sell its fertility test "Fertell"


                       "Genosis' first step into the US"



Genosis PLC, AIM:(GNOS) a company focusing on consumer products for reproductive
health, is pleased to announce that from this May, CVS, the largest drug store
chain in the United States will be selling, for the first time, its male and
female OTC fertility test Fertell.


CVS is the largest chain drug store in the US with over 6,000 stores across 43
states. Fertell will be sold through a combination of "on shelf" product, shelf
cards promoting Fertell and at www.cvs.com. The Company has received an initial
order from CVS which will be delivered to the CVS regional distribution centres
in late April.


Selling Fertell through CVS is the first step of Genosis' US distribution
strategy. Genosis anticipates that during this year, additional distribution
will be made with other chain drug and retail stores for them also to include
the Fertell product as part of their fertility merchandising programmes.


The Fertell couple test is ideally suited for the US market. Each year, in the
US, it is estimated that there are over three million couples aged 25 to 40 that
are trying to conceive. At-home fertility screening is an important and logical
first step for couples who want more information about their fertility status.
Fertell is the only FDA cleared OTC fertility test for couples and will
typically retail for $99.99.


Genosis plans to invest around $5 million on its US marketing launch campaign in
2007. US consumers will be alerted as to the availability and benefits of
Fertell through print advertising, web media and PR. In addition to selling
Fertell through chain drug stores the product is now available through
www.fertell.com.


In order to exploit and accelerate the opportunity in this highly significant US
market, the Directors' believe that further funds are required. These funds will
principally be utilised to support the marketing campaign of the Fertell product
in the US.


The Directors' are in the process of securing further financing and have already
received informal commitments from a number of institutions, including both
existing shareholders and new investors. An announcement will be made in the
near future with regards to this financing which will be conditional on the
approval of shareholders at an Extraordinary General Meeting and any necessary
regulatory approval. It is anticipated that a notice of EGM will be dispatched
to shareholders as soon as possible.



Paul Batemen, Chief Executive Officer said: "The introduction of the Fertell
product through CVS stores is a very significant milestone for the Company and a
strong reflection of the market opportunity for at-home fertility testing. This
fundraising will help us make the most of the sales potential for our innovative
product in the key US market."



For further details please contact:

Genosis PLC              Paul Bateman, CEO                   +44 (0)1483 774 051
                         Jonathan Pockson, CFO

Buchanan Communications  Lisa Baderoon                       +44 (0)20 7466 5000
                         Rebecca Skye Dietrich








                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCMGGMDNFMGNZM

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Giu 2023 a Giu 2024